Acarix AB
7AC
Company Profile
Business description
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics.
Contact
Hyllie Boulevard 34, 5TR
c/o Regus Hyllie
Malmo215 32
SWESector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,698.90 | 12.90 | -0.15% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,164.37 | 315.16 | -1.40% |
| Nikkei 225 | 55,239.40 | 1,539.01 | 2.87% |
| NZX 50 Index | 13,111.96 | 203.64 | -1.53% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,503.10 | 2.30 | -0.03% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |